Acute Promyelocytic Leukemia: A Summary
Meaghan M. Ryan, MSN, FNP-BC
Washington University School of Medicine, Saint Louis, Missouri
Author’s disclosures of conflicts of interest are found at the end of this article.
Meaghan M. Ryan, MSN, FNP-BC, 660 S. Euclid Avenue, Campus Box 8007, Saint Louis, MO 63110.
J Adv Pract Oncol 2018;9(2):178–187 |
© 2018 Harborside™
Acute promyelocytic leukemia is a distinct subtype of acute myeloid leukemia. The disease is characterized by a chromosomal abnormality involving translocation between chromosomes 15 and 17. Current therapy has advanced to include agents such as all-trans retinoic acid and arsenic trioxide, which have improved remission and survival rates. Induction, consolidation, and maintenance regimens have now been studied and are outlined. As patients affected can develop severe bleeding complications, rapid diagnosis and initiation of appropriate treatment are vital. During treatment, unique complications such as disseminated intravascular coagulation and differentiation syndrome can occur. Prompt recognition of complications is imperative.
For access to the full length article, please sign in